A panelist discusses how the ASCERTAIN-V study demonstrated that an all-oral combination of decitabine-cedazuridine plus venetoclax achieved a 47% complete response rate and 15.5-month median ...

In the subset of patients with high PARP1 expression (greater than 1.5-fold change), all were diagnosed with either ALL or AML, representing 22.03% of the total patients in the study.